PreprintCited by 7Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

PLCG2 as a Risk Factor for Alzheimer's Disease.

Open access
Tsai, Andy P., Dong, Chuanpeng, Preuss, Christoph, Moutinho, Miguel, Lin, Peter Bor-Chian, Hajicek, Nicole, Sondek, John, Bissel, Stephanie J. +6 more·2020

Abstract

Background Alzheimer's disease (AD) is characterized by robust microgliosis and phenotypic changes that accompany disease pathogenesis. Indeed, genetic variants in microglial genes are linked to risk for late-onset AD (LOAD). Phospholipase C 𝛾 2 (PLCG2) participates in the transduction of signals emanating from immune cell-surface receptors that regulate the inflammatory response and is selectively expressed by microglia in the brain. A rare variant in PLCG2 (P522R) was previously found to be protective against LOAD. Here, we performed association analysis to identify a new genetic variation in PLCG2 that is associated with elevated risk for LOAD. Methods Using whole genome sequencing (N=1,894) and RNA-Seq (N=1,077) data from the AMP-AD cohort, we investigated whether a missense variant in PLCG2 (M28L) was associated with risk for LOAD. We have examined the homology model and space-filling model of PLCG2 generated with PyMOL to investigate the protein structure of PLCG2 with substitutions of LOAD risk and protective variants in PLCG2 . Gene expression analysis and expression quantitative trait loci (eQTL) of PLCG2 were conducted. We also evaluated the relationship between PLCG2 expression levels and amyloid plaque density and expression levels of microglia specific markers ( AIF1 and TMEM119 ). Age, sex, and APOE ε4 carrier status were used as covariates. Finally, we investigated the longitudinal changes PLCG2 expression in the 5XFAD mouse model of AD and it relationship to amyloid pathology progression. Results A rare missense variant in PLCG2 (M28L) confers increased AD risk ( p =0.047; OR=1.164 [95% CI=1.002-1.351]). PLCG2 is highly expressed in the brain and was significantly up-regulated in the parahippocampal gyrus, superior temporal gyrus, and inferior temporal gyrus in LOAD. Higher PLCG2 expression levels were associated with increased brain amyloid deposition. The findings were validated in 5xFAD mice, showing a disease progression-dependent increase in Plcg2 expression with amyloid pathology. Furthermore, eQTL analysis identified several variants as associated with increased PLCG2 expression levels in the brain and other organs. Conclusions Our results provide further evidence that PLCG2 and the M28L variant confers increase risk for LOAD and may play an important role in AD pathophysiology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.21203/rs.3.rs-38216/v1

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PLCG2 polymorphisms are associated with both reduced and increased risk of Alzheimer's disease and with longevity.

    “PLCG2 polymorphisms are associated with both reduced and increased risk of Alzheimer’s disease (AD) and with longevity.”

    From Multi-omics analyses reveal novel effects of PLCγ2 deficiency in the mouse brain (2023) · cites this paper as [8]

    The Discussion reports that different PLCG2 variants may increase or reduce late-onset Alzheimer’s disease risk, and the Abstract identifies M28L as an increased-risk variant. Longevity appears only in the title of another study listed in the References; this paper does not itself report or discuss a longevity association. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 8

  1. Isik AT: Late onset Alzheimer's disease in older people. Clin Interv Aging 2010, 5:307-311.
  2. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A et al: Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet 2019, 51(3):414-430.
  3. Hernandez D, Egan SE, Yulug IG, Fisher EM: Mapping the gene that encodes phosphatidylinositol-specific phospholipase C-gamma 2 in the human and the mouse. Genomics 1994, 23(2):504-507.
  4. Walliser C, Hermkes E, Schade A, Wiese S, Deinzer J, Zapatka M, Desire L, Mertens D, Stilgenbauer S, Gierschik P: The Phospholipase Cgamma2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein. J Biol Chem 2016, 291(42):22136- 22148.
  5. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43(11):2412-2414.
  6. Hajicek N, Charpentier TH, Rush JR, Harden TK, Sondek J: Autoinhibition and phosphorylation-induced activation of phospholipase C-gamma isozymes. Biochemistry 2013, 52(28):4810-4819.
  7. Matsuda M, Paterson HF, Rodriguez R, Fensome AC, Ellis MV, Swann K, Katan M: Real time fluorescence imaging of PLC gamma translocation and its interaction with the epidermal growth factor receptor. J Cell Biol 2001, 153(3):599-612.
  8. Everett KL, Bunney TD, Yoon Y, Rodrigues-Lima F, Harris R, Driscoll PC, Abe K, Fuchs H, de Angelis MH, Yu P et al: Characterization of phospholipase C gamma enzymes with gain-of-function mutations. J Biol Chem 2009, 284(34):23083-23093.

Cited by

Sorted by citations

Authors
Tsai, A. P., Dong, C., Preuss, C., Moutinho, M., Lin, P. B.-C., Hajicek, N., Sondek, J., Bissel, S. J., Oblak, A. L., Carter, G. W., Liu, Y., Landreth, G. E., Lamb, B. T., & Nho, K.
Affiliations
  • Stark Neurosciences Research Institute
  • Indiana University School of Medicine (US)
  • Jackson Laboratory (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Nho, Kwangsik
Published
2020-06-30
OpenAlex
W4255861615
Cited by
7
References
36
Citations by year
2024: 1 · 2023: 1 · 2022: 3 · 2021: 2
Type
posted content
Language
en
Open access
Funders
  • Emory University
  • National Institutes of Health (AG054345)
  • National Institute on Aging (AG054345, AG050597, AG063250, RF1AG051495, NLM R01 LM012535, R03AG063250, AG051495, RF1AG050597, U54AG054345)
  • National Institute of General Medical Sciences (R01GM057391)
  • U.S. National Library of Medicine (R01LM012535)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, PLCγ2, late-onset Alzheimer's disease, genetic risk factors, microglia, amyloid plaques, expression quantitative trait loci, 5xFAD mice, amyloid pathology, AIF1, TMEM119, parahippocampal gyrus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review